Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

ESHRE Guideline: management of women with premature ovarian insufficiency

European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI; L. Webber, M. Davies, R. Anderson, J. Bartlett, D. Braat, B. Cartwright, R. Cifkova, S. de Muinck Keizer-Schrama, E. Hogervorst, F. Janse, L. Liao, V....

. 2016 ; 31 (5) : 926-37. [pub] 20160322

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, směrnice pro lékařskou praxi, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17013998

STUDY QUESTION: What is the optimal management of women with premature ovarian insufficiency (POI) based on the best available evidence in the literature? SUMMARY ANSWER: The guideline development group (GDG) formulated 99 recommendations answering 31 key questions on the diagnosis and treatment of women with POI. WHAT IS KNOWN ALREADY: NA. STUDY DESIGN, SIZE, DURATION: This guideline was produced by a multidisciplinary group of experts in the field using the methodology of the Manual for ESHRE Guideline Development, including a thorough systematic search of the literature, quality assessment of the included papers up to September 2014 and consensus within the guideline group on all recommendations. The GDG included a patient representative to ensure input from women with POI. After finalization of the draft, the European Society for Human Reproduction and Embryology (ESHRE) members and professional organizations were asked to review the guideline. PARTICIPANTS/MATERIALS, SETTING, METHODS: NA. MAIN RESULTS AND THE ROLE OF CHANCE: The guideline provides 17 recommendations on diagnosis and assessment of POI and 46 recommendations on the different sequelae of POI and their consequences for monitoring and treatment. Furthermore, 24 recommendations were formulated on hormone replacement therapy in women with POI, and two on alternative and complementary treatment. A chapter on puberty induction resulted in five recommendations. LIMITATIONS, REASONS FOR CAUTION: The main limitation of the guideline is that, due to the lack of data, many of the recommendations are based on expert opinion or indirect evidence from studies on post-menopausal women or women with Turner Syndrome. WIDER IMPLICATIONS OF THE FINDINGS: Despite the limitations, the guideline group is confident that this document will be able to guide health care professionals in providing the best practice for managing women with POI given current evidence. Furthermore, the guideline group has formulated research recommendations on the gaps in knowledge identified in the literature searches, in an attempt to stimulate research on the key issues in POI. STUDY FUNDING/COMPETING INTERESTS: The guideline was developed and funded by ESHRE, covering expenses associated with the guideline meetings, with the literature searches and with the implementation of the guideline. The guideline group members did not receive payment. Dr Davies reports non-financial support from Novo Nordisk, outside the submitted work; the other authors had nothing to disclose. TRIAL REGISTRATION NUMBER: NA.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013998
003      
CZ-PrNML
005      
20190517180028.0
007      
ta
008      
170413s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/humrep/dew027 $2 doi
035    __
$a (PubMed)27008889
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
110    2_
$a European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI
245    10
$a ESHRE Guideline: management of women with premature ovarian insufficiency / $c European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI; L. Webber, M. Davies, R. Anderson, J. Bartlett, D. Braat, B. Cartwright, R. Cifkova, S. de Muinck Keizer-Schrama, E. Hogervorst, F. Janse, L. Liao, V. Vlaisavljevic, C. Zillikens, N. Vermeulen,
520    9_
$a STUDY QUESTION: What is the optimal management of women with premature ovarian insufficiency (POI) based on the best available evidence in the literature? SUMMARY ANSWER: The guideline development group (GDG) formulated 99 recommendations answering 31 key questions on the diagnosis and treatment of women with POI. WHAT IS KNOWN ALREADY: NA. STUDY DESIGN, SIZE, DURATION: This guideline was produced by a multidisciplinary group of experts in the field using the methodology of the Manual for ESHRE Guideline Development, including a thorough systematic search of the literature, quality assessment of the included papers up to September 2014 and consensus within the guideline group on all recommendations. The GDG included a patient representative to ensure input from women with POI. After finalization of the draft, the European Society for Human Reproduction and Embryology (ESHRE) members and professional organizations were asked to review the guideline. PARTICIPANTS/MATERIALS, SETTING, METHODS: NA. MAIN RESULTS AND THE ROLE OF CHANCE: The guideline provides 17 recommendations on diagnosis and assessment of POI and 46 recommendations on the different sequelae of POI and their consequences for monitoring and treatment. Furthermore, 24 recommendations were formulated on hormone replacement therapy in women with POI, and two on alternative and complementary treatment. A chapter on puberty induction resulted in five recommendations. LIMITATIONS, REASONS FOR CAUTION: The main limitation of the guideline is that, due to the lack of data, many of the recommendations are based on expert opinion or indirect evidence from studies on post-menopausal women or women with Turner Syndrome. WIDER IMPLICATIONS OF THE FINDINGS: Despite the limitations, the guideline group is confident that this document will be able to guide health care professionals in providing the best practice for managing women with POI given current evidence. Furthermore, the guideline group has formulated research recommendations on the gaps in knowledge identified in the literature searches, in an attempt to stimulate research on the key issues in POI. STUDY FUNDING/COMPETING INTERESTS: The guideline was developed and funded by ESHRE, covering expenses associated with the guideline meetings, with the literature searches and with the implementation of the guideline. The guideline group members did not receive payment. Dr Davies reports non-financial support from Novo Nordisk, outside the submitted work; the other authors had nothing to disclose. TRIAL REGISTRATION NUMBER: NA.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hormonální substituční terapie $7 D020249
650    _2
$a lidé $7 D006801
650    _2
$a primární ovariální insuficience $x komplikace $x diagnóza $x terapie $7 D016649
650    _2
$a puberta $7 D011627
650    _2
$a společnosti vědecké $7 D012958
655    _2
$a časopisecké články $7 D016428
655    _2
$a směrnice pro lékařskou praxi $7 D017065
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Webber, L. $u University College London Hospital, London, UK lisa.webber@uclh.nhs.uk
700    1_
$a Davies, M $u University College London Hospital, London, UK.
700    1_
$a Anderson, R $u University of Edinburgh, Edinburgh, UK. $7 gn_A_00006170
700    1_
$a Bartlett, J $u The Daisy Network, Rossendale, UK.
700    1_
$a Braat, D $u Radboudumc Nijmegen, Nijmegen, The Netherlands.
700    1_
$a Cartwright, B $u ST5 Obstetrics and Gynaecology trainee London KSS, London, UK.
700    1_
$a Cifkova, R $u Center for Cardiovascular Prevention, Charles University in Prague, First Faculty of Medicine and Thomayer Hospital, Prague, Czech Republic.
700    1_
$a de Muinck Keizer-Schrama, S $u Erasmus University Medical Center, Sophia Children's Hospital Rotterdam, Rotterdam, The Netherlands.
700    1_
$a Hogervorst, E $u Applied Cognitive Research (SSEHS), Loughborough, UK.
700    1_
$a Janse, F $u UMC Utrecht, Utrecht, The Netherlands.
700    1_
$a Liao, L $u University College London Hospital, London, UK.
700    1_
$a Vlaisavljevic, V $u Department of Reproductive Medicine (Slovenia), University Medical Centre, Canterbury, UK.
700    1_
$a Zillikens, C $u Erasmus MC Rotterdam, Rotterdam, The Netherlands.
700    1_
$a Vermeulen, N $u European Society of Human Reproduction and Embryology, Grimbergen, Belgium.
773    0_
$w MED00002081 $t Human reproduction (Oxford, England) $x 1460-2350 $g Roč. 31, č. 5 (2016), s. 926-37
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27008889 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20190517180135 $b ABA008
999    __
$a ok $b bmc $g 1200463 $s 974776
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 31 $c 5 $d 926-37 $e 20160322 $i 1460-2350 $m Human reproduction $n Hum. reprod. (Oxf., Print) $x MED00002081
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Možnosti archivace